Antisense Therapeutics receives FDA orphan designation for muscular dystrophy treatment

Antisense Therapeutics chief executive Mark Diamond says the Melbourne biotech has hit a “very significant commercial milestone” after US regulators … Read More

The post Antisense Therapeutics receives FDA orphan designation for muscular dystrophy treatment appeared first on Stockhead.

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *